Physique II 2, 16311656 (1992)
The Weight Loss Diabetes Drug Market size is expected to reach USD 37.48 billion in 2026 and grow at a CAGR of 5.21% to reach USD 48.27 billion by 2031
Purchase is restricted to qualified professionals and institutions aged 18 or over
Relying on the RDA alone 0.8 g/kg prevents deficiency but is low for active adults, older adults, and anyone losing weight on GLP-1
Its current menu, verified July 2026, is compounded semaglutide injection, compounded tirzepatide injection, and a dissolvable GLP-1 tablet taken once daily, alongside branded Wegovy and Zepbound options routed through a separate membership
PlexusDx compounded GLP-1 options (including our Microdose GLP-1 Protocol at $129/month) allow flexible, provider-guided dosing strategies tailored to individual needs